Long-term rates of undetectable PSA with initial observation and delayed salvage radiotherapy after radical prostatectomy.
BACKGROUND
Randomized trials have shown an improvement in progression-free survival rates with adjuvant radiation therapy (ART) after radical prostatectomy for patients with a high risk of cancer recurrence. Less is known about the relative advantages and disadvantages of initial observation with delayed salvage radiation therapy (SRT).


OBJECTIVE
To examine the results of SRT in a large single-surgeon radical prostatectomy series.


METHODS
From a radical prostatectomy database, we identified 859 men with positive surgical margins (SM+), extracapsular tumor extension (ECE), or seminal vesicle invasion (SVI) who chose to defer ART. Following a period of initial observation, 192 ultimately received SRT for prostate-specific antigen (PSA) progression.


METHODS
Survival analysis was performed to examine the outcomes of initial observation followed by SRT.


CONCLUSIONS
In patients with SM+/ECE and SVI, the 7-yr PSA progression-free survival rates with observation were 62% and 32%, respectively. Among those who had PSA progression, 56% and 26%, respectively, maintained an undetectable PSA for 5 yr after SRT. The long-term rates of undetectable PSA associated with an SRT strategy were 83% and 50% for men with SM+/ECE and SVI, respectively. In the subset of 716 men who did not receive any hormonal therapy, the corresponding long-term rates of undetectable PSA were 91% and 75%, respectively.


CONCLUSIONS
Following radical prostatectomy, initial observation followed by delayed SRT at the time of PSA recurrence is an effective strategy for selected patients with SM+/ECE. Some patients with SVI may also benefit from this strategy. However, additional prospective studies are necessary to further examine the survival outcomes following SRT.
Loeb
Stacy
S
Department of Urology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Roehl
Kimberly A
KA
Viprakasit
Davis P
DP
Catalona
William J
WJ
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000532:radiotherapy* / Q000601:surgery*; D016879:Salvage Therapy; D016019:Survival Analysis; D013997:Time Factors
D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen